Partners
Precision Therapeutics. Advanced Together.
No single company can make precision therapeutics for acute illness a reality. We partner with diagnostic companies, academic research sites, pharmaceutical companies, and healthcare IT vendors who share our commitment to matching patients with the therapies most likely to help them.
Prenosis has partnered with Roche to make Sepsis ImmunoScore® available through Roche’s navify® Algorithm Suite, which brings together evidence-based, certified algorithms for hospitals and lab managers in one platform. The collaboration pairs Roche’s global distribution and clinical standards with Prenosis’ FDA De Novo-authorized AI diagnostic, extending access to more U.S. hospitals.
Prenosis is collaborating with BioAegis Therapeutics to identify the patients most likely to benefit from BioAegis’s recombinant plasma gelsolin therapy, an immune modulator being studied in a Phase 2 trial for moderate-to-severe ARDS. Using biospecimens and clinical data from that trial, Prenosis’ AI platform is identifying the biological signatures that predict response, applying precision patient selection to a therapy already in clinical development.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.